TABLE 1.
Demographic and clinical data from two patient groups
| Characteristic | Bismuth quadruple therapy (n = 164) | Hybrid therapy (n = 166) | P value |
|---|---|---|---|
| Age (yr) (mean ± SD) | 53.46 ± 12.28 | 54.48 ± 11.45 | 0.43 |
| Sex (no. male/no. female) | 94/70 | 79/87 | 0.07 |
| Smoking (n [%]) | 36 (22) | 39 (19.9) | 0.64 |
| Consumption (n [%]) | |||
| Alcohol | 8 (4.9) | 8 (4.8) | 0.98 |
| Coffee | 39 (23.8) | 40 (24.1) | 0.94 |
| Tea | 46 (28) | 45 (27.1) | 0.84 |
| NSAIDa use (n [%]) | 2 (1.2) | 2 (1.2) | 1.00 |
| Underlying disease (n [%]) | 38 (23.2) | 47 (28.3) | 0.28 |
| Endoscopic findings (n [%]) | |||
| Gastritis | 86 (52.4) | 72 (43.4) | 0.10 |
| Peptic ulcer | 78 (47.6) | 94 (56.6) | 0.10 |
| Antibiotic resistanceb (% [no./total]) | |||
| Clarithromycin | 15.8 (6/38) | 17.6 (6/34) | 0.83 |
| Amoxicillin | 2.6 (1/38) | 0 (0/34) | —c |
| Metronidazole | 26.3 (10/38) | 23.5 (8/34) | 0.78 |
| Tetracycline | 0 (0/38) | 0 (0/34) | — |
a
NSAID, nonsteroidal anti-inflammatory drug.
b
Seventy-two strains were isolated.
c
—, not applicable.